Skip to main content
Premium Trial:

Request an Annual Quote

Exelixis, French Researchers Uncover Immune-Modulating Pathway

NEW YORK, April 18 - Researchers from Exelixis and the French Centre National de la Recherche Scientifique have used the company's model mutagenesis approach to characterize a new biological pathway in the innate immune response.

 

In the work, documented in an article in the April 11 issue of Nature, researchers described the activity of the gene peptidoglycan recognition protein-LC in Drosophila. In response to bacterial infection, the researchers say, this gene triggers a pathway that activates a key inflammatory gene.

 

The two teams transformed a fly with a disrupted PGRP-LC gene, and the resulting organism was rendered vulnerable to Gram-negative bacterial sepsis, due to a malfunctioning immune response.

 

Because the gene is highly conserved, the researchers hope that the discovery may shed light on human innate immunity and inflammatory disease. The function of the homologue protein in humans has not yet been characterized.

 

Exelixis and CNRS researchers plan to continue studying the gene's role in the immune response with the goal of developing new drug targets for treatment of human inflammatory disorders, said Exelixis president and CEO George Scangos.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more